Atlas Trials

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

Clinical trial NCT02454179 · COMPLETED

Trial details

NCT number
NCT02454179
Sponsor
Acerta Pharma BV
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Squamous Cell Carcinoma of the Head and Neck
Start date
2015-05-01
Primary completion
2018-05-01
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.